Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

1.494 -0.016 (-1.05%)
Streaming Delayed Price Updated: 11:08 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
The trading volume of these stocks is deviating from the norm in today's session.
Unusual volume stocks are being observed in Tuesday's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Earnings Outlook For BioRestorative Therapies
 
Via Benzinga
Earnings Preview For BioRestorative Therapies
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
From Phase 2 Trial Results To Expansion Mode: A Look At BioRestorative's Novel Approach To Treating Chronic Pain
Via TheNewswire.com
BioRestorative Announces Share Repurchase Program
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based 
Via PressReach
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based 
Via PressReach
BioRestorative Welcomes Serial Regenerative Medicine Entrepreneur, Company Builder and Leader, Sandy Lipkins, to BRTX Team
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based 
Via PressReach
BioRestorative to Present Major Update on Promising Preliminary Phase 2 BRTX-100 Data at ISSCR 2025
BioRestorative Therapies, Inc. (“BioRestorative,” “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical-stage regenerative medicine company developing stem cell-based 
Via PressReach
Uncovering Potential: BioRestorative Therapies's Earnings Preview
 
Via Benzinga
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Earnings Scheduled For May 14, 2025
 
Via Benzinga
Leveraging Stem Cells To Fight Chronic Lower Back Pain And Obesity With BioRestorative Therapies
Via TheNewswire.com
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease
By Meg Flippin Benzinga 
Via TheNewswire.com
Which stocks have an unusual volume on Thursday?
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
Earnings Scheduled For March 27, 2025
 
Via Benzinga
On Tuesday, there are stocks with unusual volume. Let's take a look.
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial 
Via News Direct
Topics Intellectual Property
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market
Presenting Encouraging Data, Acquiring Licenses, Issuing Patents And More – BioRestorative's Inroads Bringing Its Stem Cell Therapies To Market 
Via News Direct
Topics Intellectual Property
BioRestorative Therapies Lower Back Candidate Shows Decrease In Pain, Increased Function
BioRestorative Therapies shares promising Phase 2 trial results for BRTX-100, showing significant pain reduction and functional improvement in cLDD patients. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?
Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind? 
Via News Direct
Topics Intellectual Property
BRTX Stock Earnings: BioRestorative Therapies Beats EPS, Beats Revenue for Q2 2024
BRTX stock results show that BioRestorative Therapies beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
What's Going On With BioRestorative Therapies Stock?
BioRestorative Therapies shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with listing requirements. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.